| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Onkure Therapeutics, Inc. (OKUR) has 13 insiders with recent SEC Form 4 filings, including 11 buys and 0 sells. OKUR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.71M | $5.81M | - | |
| CEO | 330.0K | $1.12M | - | |
| CFO | 110.0K | $374.0K | - | |
| Other | 110.0K | $374.0K | - | |
| Other | 110.0K | $374.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2021 | Muralidhar Bali | Director | Buy | 16,605 | $9.50 | $157,709.31 | +0.9% | -7.8% | -76.1% | |
| Jun 4, 2021 | Muralidhar Bali | Director | Buy | 12,357 | $9.26 | $114,365.17 | +0.3% | -6.4% | -77.1% | |
| May 28, 2021 | Muralidhar Bali | Director | Buy | 14 | $9.50 | $133.00 | - | -37.5% | -79.3% | |
| May 27, 2021 | Muralidhar Bali | Director | Buy | 7,035 | $9.36 | $65,864.42 | +0.2% | -27.1% | -78.5% | |
| Apr 13, 2021 | Muralidhar Bali | Director | Buy | 200,000 | $15.00 | $3,000,000.00 | +12.1% | -26.7% | -77.4% | |
| Apr 13, 2021 | New Enterprise Associates 15, L.P. | 10% Owner | Buy | 666,666 | $15.00 | $9,999,990.00 | +16.2% | -26.7% | -77.4% | |
| Apr 13, 2021 | Novo Holdings A/s58 | 10% Owner | Buy | 666,666 | $15.00 | $9,999,990.00 | +24.1% | -26.7% | -77.4% | |
| Apr 13, 2021 | O'Donnell Niall | Director | Buy | 200,000 | $15.00 | $3,000,000.00 | +10.7% | -26.7% | -77.4% | |
| Apr 9, 2021 | Rivervest Venture Fund Iii, L.P. | 10% Owner | Buy | 200,000 | $15.00 | $3,000,000.00 | +9.1% | -37.1% | -79.2% |